Other
Monotherapy
0
Pipeline Programs↗
15
Active Trials↗
37
Companies Involved↗
Monotherapy is an early-stage landscape with 0 programs across 37 companies. The most active players are AstraZeneca, GSK, Ardea Biosciences, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
144
clinical trials
Completed92 · 64%
Terminated16 · 11%
Unknown status16 · 11%
Recruiting8 · 6%
Withdrawn5 · 3%
Active, not recruiting4 · 3%
Other3 · 2%
Clinical Trials
Trial Activity
144 trials
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06106152·20 enrolled
Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection
Recruiting·—·Phase 4·NCT06570850·188 enrolled
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06958705·79 enrolled
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients
Active, not recruiting·IInternational Extranodal Lymphoma Study Group (IELSG)·Phase 3·NCT05735834·122 enrolled
A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
Not yet recruiting·—·Phase 2·NCT06476899·60 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)